Description of the medicine: Mirtazapine (Mirtazipine)
1,2,3,4,10,14b-Hexahydro-2-methylpyrazino- [2,1-a] pyrido [2,3-c] benzazepine.
Synonym: Remeron, Remeron.
White to off-white crystalline powder. Slightly soluble in water.
Refers to the "balanced" antidepressants with a predominance of anxiolytic and sedative effects.
It has a special mechanism of action - selectively blocks central presynaptic A2-adrenergic receptors and postsynaptic 5-HT2- and 5-HT3-serotonin receptors, resulting in improved adrenergic and serotonergic transmission.
In addition, it is an active blocker of H1-histamine and moderately active - m-cholinergic receptors.
After oral administration, it is rapidly and completely absorbed, bioavailability is 50%, Сmax - 2 hours, T1 / 2 - 24-37 hours; excreted mainly in urine.
Used for endogenous depression of various etiologies. Assign inside adults to 0.03-0.045 g (30-45 mg) once a day (at night). The clinical effect usually develops after 1-2 weeks. Duration of treatment is up to 6 months.
When using the drug, a number of side effects are possible: sedation, extrapyramidal disorders, myoclonus, paresthesia, dystonia, migraine, arrhythmias, inhibition of blood formation, jaundice, urinary retention, myasthenia gravis, disturbance of accommodation, allergic reactions, etc.
The drug is contraindicated in renal and hepatic insufficiency, infectious and cardiovascular diseases, pregnancy, breastfeeding.
Incompatible with MAO inhibitors.
Release form: tablets on 0,015; 0.03 and 0.045 g (15, 30 and 45 mg) (N. 10, 30).
Storage: List B.